PMC:7283670 / 71634-72011 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T259","span":{"begin":165,"end":170},"obj":"Body_part"}],"attributes":[{"id":"A259","pred":"fma_id","subj":"T259","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T159","span":{"begin":165,"end":170},"obj":"Body_part"}],"attributes":[{"id":"A159","pred":"uberon_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T631","span":{"begin":159,"end":164},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T254","span":{"begin":180,"end":188},"obj":"Chemical"},{"id":"T255","span":{"begin":259,"end":261},"obj":"Chemical"},{"id":"T256","span":{"begin":372,"end":377},"obj":"Chemical"}],"attributes":[{"id":"A254","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group"}

{"project":"LitCovid-sentences","denotations":[{"id":"T677","span":{"begin":0,"end":377},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1852","span":{"begin":165,"end":178},"obj":"Gene"},{"id":"1918","span":{"begin":64,"end":76},"obj":"Species"},{"id":"2048","span":{"begin":159,"end":164},"obj":"Species"}],"attributes":[{"id":"A1852","pred":"tao:has_database_id","subj":"1852","obj":"Gene:213"},{"id":"A1918","pred":"tao:has_database_id","subj":"1918","obj":"Tax:9606"},{"id":"A2048","pred":"tao:has_database_id","subj":"2048","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group"}